Bruker Acquisition of BioSpin Clears Antitrust Period; Shareholders' Meeting Scheduled | GenomeWeb
NEW YORK (GenomeWeb News) – Bruker BioSciences said today that the Hart-Scott-Rodino waiting period for its proposed acquisition of affiliate Bruker BioSpin has expired.
 
Bruker BioSciences announced in early December that it had launched a $914 million takeover of Bruker BioSpin, which is 100 percent owned by members of the Laukien family, who also own 52 percent of publicly traded Bruker BioSciences.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.